CN113968913A - 抗cd70嵌合抗原受体 - Google Patents

抗cd70嵌合抗原受体 Download PDF

Info

Publication number
CN113968913A
CN113968913A CN202111253336.5A CN202111253336A CN113968913A CN 113968913 A CN113968913 A CN 113968913A CN 202111253336 A CN202111253336 A CN 202111253336A CN 113968913 A CN113968913 A CN 113968913A
Authority
CN
China
Prior art keywords
amino acid
pro
car
arg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111253336.5A
Other languages
English (en)
Chinese (zh)
Inventor
王琼
余致亚
詹姆斯·C·阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN113968913A publication Critical patent/CN113968913A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202111253336.5A 2014-12-08 2015-04-09 抗cd70嵌合抗原受体 Pending CN113968913A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088882P 2014-12-08 2014-12-08
US62/088,882 2014-12-08
CN201580066498.4A CN107207616B (zh) 2014-12-08 2015-04-09 抗cd70嵌合抗原受体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580066498.4A Division CN107207616B (zh) 2014-12-08 2015-04-09 抗cd70嵌合抗原受体

Publications (1)

Publication Number Publication Date
CN113968913A true CN113968913A (zh) 2022-01-25

Family

ID=52997584

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111253336.5A Pending CN113968913A (zh) 2014-12-08 2015-04-09 抗cd70嵌合抗原受体
CN201580066498.4A Active CN107207616B (zh) 2014-12-08 2015-04-09 抗cd70嵌合抗原受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580066498.4A Active CN107207616B (zh) 2014-12-08 2015-04-09 抗cd70嵌合抗原受体

Country Status (12)

Country Link
US (3) US10689456B2 (enExample)
EP (3) EP3597663B1 (enExample)
JP (3) JP6724009B2 (enExample)
CN (2) CN113968913A (enExample)
AU (3) AU2015361261B2 (enExample)
CA (1) CA2970280A1 (enExample)
DK (1) DK3597663T3 (enExample)
ES (2) ES2745153T3 (enExample)
PL (1) PL3230310T3 (enExample)
PT (1) PT3230310T (enExample)
SI (1) SI3230310T1 (enExample)
WO (1) WO2016093878A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6724009B2 (ja) * 2014-12-08 2020-07-15 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体
CN105949325B (zh) * 2016-07-08 2019-07-16 重庆精准生物技术有限公司 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
AU2017307610B2 (en) * 2016-08-04 2023-10-05 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2019051047A1 (en) * 2017-09-07 2019-03-14 University Of Florida Research Foundation, Inc. CHIMERIC ANTIGEN RECEPTOR T-LYMPHOCYTES EXPRESSING THE INTERLEUKIN-8 RECEPTOR
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
JP7542441B2 (ja) * 2018-05-11 2024-08-30 クリスパー セラピューティクス アクチェンゲゼルシャフト 癌を治療するための方法及び組成物
KR20210038922A (ko) * 2018-08-02 2021-04-08 카이트 파마 인코포레이티드 키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
CN109880802B (zh) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
EP3962498A4 (en) * 2019-04-30 2023-05-31 Memorial Sloan Kettering Cancer Center Combination therapies
US20200384278A1 (en) * 2019-06-04 2020-12-10 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for Combination Cold Atmospheric Plasma and CAR-T Therapy
US20220411478A1 (en) * 2019-09-16 2022-12-29 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
MX2022008485A (es) * 2020-01-08 2022-08-02 Univ Texas Un metodo para modificar celulas asesinas naturales para dirigirse a tumores positivos a cd70.
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
EP4262825A1 (en) * 2020-12-15 2023-10-25 Universiteit Antwerpen Cell-based therapeutics targeting cd70
KR20230136184A (ko) * 2021-01-25 2023-09-26 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Cd70-양성 종양을 표적화하기 위한 cd27-세포외 도메인 car
US20220378829A1 (en) * 2021-05-12 2022-12-01 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2023072307A1 (zh) * 2021-10-25 2023-05-04 重庆精准生物技术有限公司 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
CN117924489A (zh) * 2022-01-19 2024-04-26 上海恒润达生生物科技股份有限公司 抗cd70纳米抗体及其用途
JP2025511914A (ja) * 2022-04-07 2025-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作されたナチュラルキラー細胞の活性化および増殖方法と抗体との組み合わせ
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501816A (zh) * 2010-10-27 2014-01-08 贝勒医学院 使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体
US20140037628A1 (en) * 2011-04-08 2014-02-06 The United States of America, as rep., by the Secretary, Dept., of Health and Human Services. Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014070957A1 (en) * 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
CN103946242A (zh) * 2011-10-20 2014-07-23 美国卫生和人力服务部 抗cd22嵌合抗原受体
CN104159909A (zh) * 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001049A2 (en) * 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
JP6724009B2 (ja) * 2014-12-08 2020-07-15 アメリカ合衆国 抗ｃｄ７０キメラ抗原受容体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501816A (zh) * 2010-10-27 2014-01-08 贝勒医学院 使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体
US20140037628A1 (en) * 2011-04-08 2014-02-06 The United States of America, as rep., by the Secretary, Dept., of Health and Human Services. Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN103946242A (zh) * 2011-10-20 2014-07-23 美国卫生和人力服务部 抗cd22嵌合抗原受体
CN104159909A (zh) * 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014070957A1 (en) * 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Also Published As

Publication number Publication date
JP7574243B2 (ja) 2024-10-28
AU2020203836B2 (en) 2021-09-09
JP2020171292A (ja) 2020-10-22
CN107207616B (zh) 2021-11-19
EP4043487A1 (en) 2022-08-17
EP3230310B1 (en) 2019-06-12
JP7128860B2 (ja) 2022-08-31
AU2021277627B2 (en) 2023-08-24
WO2016093878A1 (en) 2016-06-16
JP6724009B2 (ja) 2020-07-15
CA2970280A1 (en) 2016-06-16
CN107207616A (zh) 2017-09-26
AU2015361261A1 (en) 2017-06-15
EP3597663A1 (en) 2020-01-22
AU2021277627A1 (en) 2021-12-23
ES2745153T3 (es) 2020-02-27
PT3230310T (pt) 2019-09-26
ES2921208T3 (es) 2022-08-19
AU2015361261B2 (en) 2020-03-12
EP3230310A1 (en) 2017-10-18
PL3230310T3 (pl) 2020-02-28
DK3597663T3 (da) 2022-06-27
SI3230310T1 (sl) 2019-11-29
AU2020203836A1 (en) 2020-07-02
US11999796B2 (en) 2024-06-04
JP2022137020A (ja) 2022-09-21
US20240294665A1 (en) 2024-09-05
US20200317807A1 (en) 2020-10-08
US10689456B2 (en) 2020-06-23
EP3597663B1 (en) 2022-04-06
US20180208671A1 (en) 2018-07-26
JP2018505139A (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
AU2021277627B2 (en) Anti-CD70-chimeric antigen receptors
JP7755890B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
CN111094345B (zh) 具有人结构域的抗b细胞成熟抗原嵌合抗原受体
AU2016338747B2 (en) Anti-CD30 chimeric antigen receptors
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
HK40021099B (en) Anti-cd70 chimeric antigen receptors
HK40021099A (en) Anti-cd70 chimeric antigen receptors
WO2024097637A1 (en) Hla-a3-restricted t cell receptors against braf with v600e mutation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination